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Opportunities to improve production processes and access to markets through the 
implementation of lean manufacturing in biomedical manufacturing are presented. 
The importance of a unified definition of manufacturing, to which biomedical 
manufacturing is party, is emphasized, and the theory of “lean”, summarized as 
“purpose, process, people”, is elaborated. The requirements for the creation of 
value through the creation of flow and the elimination of wastes are highlighted in 
the context of biomedical manufacturing. Finally, case studies are presented to 




Geleenthede vir die verbetering van produksieprosesse en marktoegang via die 
implementering van skraalvervaardiging in die biomediese vervaardigingsbedryf 
word voorgehou.  Aandag word geskenk aan die betekenis van terme soos “skraal, 
doel, proses, menes” in die konteks van biomediese vervaardiging. Waardeskepping, 
vloei en vermorsing word onder die loep geneem.  Gevallestudies word ter illustrasie 
van begrippe aangebied. 
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1.  INTRODUCTION AND BACKGROUND 
 
Biomedical manufacturing describes manufacturing operations that take place in a 
very challenging environment where quality standards are very high and where 
tolerance to faulty equipment or devices is nearly zero. The definition of 
“manufacturing” itself, however, is difficult because of the nature of the various 
industries in which manufacturing takes place. In the fabrication and assembly of a 
product, however, it is the rule rather then the exception that a product is made up 
from several components that are produced by a number of different industries. It 
would therefore be beneficial to have a common definition of what every 
participant understands “manufacturing” to be, to ensure that everyone is working 
off the same platform. 
 
The US Census Bureau’s North American Industry Classification System (NAICS) [1] 
classifies an establishment as being in the manufacturing sector if it is “engaged in 
the mechanical, physical, or chemical transformation of materials, substances, or 
components into new products.” This definition is very broad; even preparing fast-
food burgers would have to be considered manufacturing according to this 
definition. It therefore requires further clarification.  
 
The FDA’s definition of manufacturing [2] is equally broad and even ambiguous. 
Section 820.3 defines a manufacturer as “any person who designs, manufactures, 
fabricates, assembles, or processes a finished device”. According to this definition, 
a supplier of a semi-finished product would not be a manufacturer. However, a 
company that produces components that will be used in a dialysis machine will 
certainly be subject to the same quality standards and regulations as the 
manufacturer of the dialysis machine itself. The FDA then qualifies its own 
definition by stating that a “Manufacturer includes but is not limited to those who 
perform the functions of contract sterilization, installation, relabeling, 
remanufacturing, repacking, or specification development, and initial distributors of 
foreign entities performing these functions”.  
 
The definitions presented by the Census Bureau and by the FDA refer to 
manufacturing as a set of operations, without unambiguously defining the term 
“manufacturing”. The definitions neglect, for example, the importance of quality 
control and continuous improvement of production processes in manufacturing. With 
regard to the biomedical industry, the effects of this short-coming will make 
themselves felt as the industry matures and manufacturing in this industry is 
subjected to cost-cutting and continuous quality improvements. This different 
manufacturing approach is already being practised today in the automotive or 
semiconductor industry, under the headline of “lean manufacturing”. 
 
2.  LEAN MANUFACTURING 
 
Lean manufacturing originated at Toyota in Japan in the 1950s [3], as a response to 
the short-comings of the traditional batch-and-queue mass production approach 
practised in the automotive industry. These short-comings included a number of 
factors, most notably the enormous tie-up of working capital in inventories and 
work-in-process, the amount of rework to be carried out before a vehicle can be 
sold to the customer, the inability to respond to changing consumer demands, and 
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the unwillingness of narrow-skilled employees to improve production processes, for 
fear of losing their jobs in the process. The lean manufacturing approach pioneered 
by Toyota has come to be known as the Toyota Production System (TPS). The system 
can be characterized by three key elements: purpose, process, people. At the 
center of the TPS is the creation of value, from the perspective of the customer. 
The purpose of Toyota’s operations then is the production of motor vehicles that 
the customer wants, as opposed to those which the company thinks the customer 
will want. The effect of this perspective is that it reverses the manufacturing 
process: raw materials, parts and components are not pushed through the factory, 
but are pulled by the customer. In order to respond to changing customer demands, 
Toyota’s operation had to develop highly flexible processes, allowing quick change-
over times to accommodate these customer demands (vehicle colour, vehicle 
customization, etc.). If a process must be set up in a way that it creates value for 
the customer, a critical parameter is introduced into a company’s operation: the 
flow of a product. If a product flows through assembly, then it greatly improves 
response to customer orders and reduces the tie-up of working capital referred to 
above. Product flows, among other benefits, reduce delivery times to the customer. 
The pull of the customer ensures that only those products or services are built or 
provided that are actually demanded by the customer. This frees up capacity for 
new product development. Additionally, it enables the companies to increase their 
product diversity, which is a typical benefit of lean thinking [3]. In order to operate 
these new processes, the employees (i.e., people) had to be (a) equipped with a 
much broader skill set, (b) empowered to make decisions while they assembled the 
vehicle, and (c) helped to eliminate wasteful steps along the path of production. 
These decisions concerned how to arrange the assembly steps and what to do with 
defective components received from upstream processes (in-house or suppliers).  
 
It is important to recognize the order in which lean manufacturing proceeds. The 
reduction of waste (i.e., cost reduction) may take place only after flow of the 
product has been created. Cost reduction in itself is a valuable approach, but the 
amount of wasteful activity in an operation will only become fully visible once 
product flow has been introduced. 
 
TPS has been copied and adapted since the 1980s by nearly all Western automotive 
OEMs. The most visible effects to the consumer include an increase in product 
diversity and a reduction of inventories. 
 
The author therefore offers the following definition of manufacturing: 
“Manufacturing is a team process of creating more than one semi-finished or 
finished consumer product out of materials, substances or components through 
mechanical, physical or chemical treatment or transformation. In the ideal 
situation, manufacturing encompasses a systematic approach to flowing the product 
at the pull of the customer in pursuit of perfection, identifying and eliminating 
waste through continuous improvement.” 
 
This definition offers several advantages over those described before. First, this 
definition is not specifying a particular target industry. It is therefore universally 
applicable to OEMs as well as to suppliers of various disciplines, such as electronics, 
mechatronics, polymer sciences, packaging, or product sterilization. Proceeding in 
this way ensures that all participants in product development and sales are 
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proceeding from the same platform. Second, the definition demands that the 
product flows, and that it does so at the pull of the customer. Third, this definition 
challenges the participants continuously to improve their production processes. If 
the quality of a production process is improved, then the contingencies for product 
liability can be reduced as well, thereby freeing up capital for innovations and 
reducing overall rising health costs [4]. Examples of such paradigm shifts and the 
associated changes in the manufacturing processes will be presented below. The 
“pursuit of perfection” implies that this is a never-ending process, as there are 
always wastes (waiting, rework, transport, inventory, etc.) involved with 
operations.  
 
The author’s position therefore is that manufacturing in the biomedical industry is 
certainly subject to industry-inherent liability and legal, volumetric, quality, 
biological and other constraints. The flow of the value stream, however, must be 
mapped, followed and optimized like in any other industry.  
 
Purpose – creating value for consumers in unregulated markets 
 
An example of an unregulated medical device market is South Africa [5]. The 
general requirement of end users, such as private hospitals, is that the products 
imported into South Africa either are FDA-approved or carry the CE-mark. This 
applies particularly to high-risk products such as pacemakers or CT scans. Such 
electro-mechanical devices today must be registered with the Radiation Control 
Directorate (DRC) under the Ministry of Health. To import a product into South 
Africa, the company must submit a government-issued form, together with a 
manufacturer-issued colour brochure of the imported product, a letter of 
appointment stating that the importer is an authorized representative of the 
manufacturer, as well as EC certificates and the EC Declaration of Conformity issued 
by the manufacturer. Duties are not payable on medical and laboratory equipment. 
However, all imported items are subject to the value-added tax (VAT) applicable at 
the time of importation. 
 
Monitoring the safe use of radiation equipment comes under the purview of the DRC. 
For this purpose, regular inspections are carried out at medical institutions and 
industrial premises in order to ensure that patients, personnel, and members of the 
public are protected from radiation. 
 
Regulations for medical devices are currently being drafted. The European medical 
devices directive has been used as a basis for the classification of products. Only 
products with either FDA approval or CE marking (or an equivalent approved 
certification) are allowed to be registered. These draft regulations will contain 
specifications on the import licensing, labeling requirements, and post-market 
obligations of the license holder. Procedures for reporting and handling of adverse 
events and other post-market surveillance activities are likely to be established.  
 
The introduction of regulations for medical devices in South Africa will also make it 
necessary to establish a local certification authority. It will be impossible, from both 
financial and geographic considerations, to rely on European certification authorities 
if medical device regulations are not to prejudice local small and medium size 








Figure 1b:  Stent strut cut with fibre laser (Courtesy of Rofin-Baasel) 
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Case study for process improvement through better tools 
 
The progress made in manufacturing over the past decade can best be illustrated by 
the advances made with regard to advanced materials and manufacturing processes. 
Figure 1 shows the walls of a laser-cut stent. Stents are small scaffolding devices 
made from stainless steel 316L, shape memory alloys such as Nitinol, or co-alloys. 
The wall of the stent shown in Figure 1a was cut with an Nd:YAG laser, whereas the 
wall of the stent in Figure 1b was cut with a fibre laser. Although the magnification 
between Figures 1a and 1b is different, it can be seen that the surface roughness of 
the stent wall cut with the Nd:YAG laser is considerably rougher than in the case of 
the fibre laser cut stent wall. Nd:YAG lasers were the tool of choice from the 
beginning of commercial stent cutting until just a few years ago. Their ability to 
focus into a spot size of several hundred micrometers diameter, and the 
repeatability of the laser operation, meant that automated stent cutting out of 
small diameter metal pipes was possible. With the market introduction of fibre 
lasers of hundreds of watts of output power over the past five years, it became 
possible to install fibre lasers for stent cutting instead of Nd:YAG lasers. The usage 
of fibre lasers is highly attractive, due to this laser beam’s ability to focus into an 
even smaller spot size than Nd:YAG lasers. Strut widths as small as 10 micrometers 
can be achieved (Figure 2). This property then enables a stent designer to create 
even more filigree struts and curvatures (Figure 3). Another example of the degree 
of freedom given to designers by the introduction of stent cutting with fibre laser is 
shown in Figure 4. 
 
Processing of advanced materials 
 
Often when advanced materials are developed for particular applications, 
conventional machining and processing techniques cannot be employed. Micro-
actuators for endoscopic surgery might have to be generated from shape memory 
alloys. However, forming or joining such materials is very challenging because the 
materials’ properties may not be lost or destroyed during the machining process. 
 
In a truly baseline investigation of the weldability of commercially available binary 
nickel-titanium shape memory alloys using an Nd:YAG laser, Haas [6] analyzed the 
behaviour of 50.5 at-% and 48.5 at-% containing Titanium (henceforth referred to as 
Ni51Ti alloy and Ni49Ti alloy). The author carried out his investigations with an eye on 
micromachining shape memory alloys in sheet-form; he therefore selected sheet 
metal thickness for both alloys of 0.5 mm and 0.17 mm. The author documented 
that the laser-welded martensitic Ni49Ti alloy retained its shape-memory effect up 
to a strain of 6 % without failure. The laser-welded joints exhibited a free recovery 
with an amnesia of 0.3 %. The ultimate tensile strength of the laser-welded region 
was 600 MPa, compared to 1200 MPa of the base material. This reduction was 
attributed to the formation of Ti2Ni precipitations along the grain boundaries. The 
Ni51Ti alloy exhibited an ultimate tensile strength of 820 MPa and a full elastic range 
of 7 % strain, with a permanent set of 0.15 %. The author concluded that Nd:YAG 










Figure 3:  Laser-cut spiral in stent (Courtesy of Rofin-Baasel) 
 
 
Training people – Education 
 
Looking at the education of engineers, this approach to (biomedical) manufacturing 
carries many implications for the engineering qualification. First, an understanding 
of the complexity of a biological system must be conveyed. While the system’s 
mechanisms and demands find some simple analogies for pulsating flows (heart, 
organs, and muscles) or statics (skeleton), an analogy to the prevention of restinosis 
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formation by means of drug-eluting stents is much more complex. The complexity of 
a biological system can be illustrated from the area of orthopaedics by 
complications after hip replacements. Some patients are at risk of developing 
heterotopic ossification, a non-malignant overgrowth of the bone [7]. Calcification is 




Figure 4:  An example of the available degree of freedom for stent design 
(Courtesy of Rofin-Baasel) 
 
Further, the manufacturing engineer must be taught to prevent massive work-in-
process and build-up of inventory. To accomplish this, he must gain an appreciation 
for the economical constraints imposed by inventory build-up and the risks 
introduced when machining or design errors are identified only after products have 
been sold and large inventories of defective components or products have been 
built-up.  
 
This concept of “lean thinking” can be taken further than just the engineering level. 
Medical doctors at Flinders University Hospital in Adelaide, Australia, led by Ben-
Tovim et al [8], identified new paths for redesigning patient treatment and care. 
This group has implemented a lean approach to hospital care that enabled them 
literally to reduce the number of patients dying in their care. Their starting point 
was to observe the path (flow) of the patient through the hospital from the 
patient’s first presentation to being discharged. This approach leaves behind the 
“departmental thinking” and maps the horizontal way that a patient (i.e., customer) 
takes through the vertically-organized departments and specialties in a hospital. 
Contrary to the general perception that in an emergency room one “does not know 
what comes through the door next”, the authors were able to increase their 
emergency room throughput by 20 % and also accelerate turn-over in wards by 20 %. 
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This was accomplished by standardizing procedures and by optimizing the patient’s 
“flow” through the organization.  
 
Health care as a whole (to which biomedical manufacturing is party) therefore must 
be open to alternative “production” approaches. Teaching engineering at higher 
education institutions in particular must instill in tomorrow’s engineers the ability to 
look at a process from a customer’s (i.e., patient’s) perspective. Apparently purely 
economical considerations about work-in-process and inventory build-up carry 
engineering penalties, in the form of rework and recalls, continuous prioritizing of 





Figure 5:  Orthopaedic Distal Ulna Arthroplasty (Courtesy of ISIQU) 
 
Case study in orthopaedics 
 
Replications of almost the entire human skeleton have been developed over the past 
20 years, and there is a wide range of OEMs from all over the world to choose from. 
The most widely known examples of orthopaedic implants are probably titanium 
screws for bone fixation and hip and knee replacements. Figures 5 and 6 show 
arthroplasties of the Distal Ulna and the Distal Radius respectively. These 
arthroplasties were developed to replace cancerous bone material. As the extent of 
the progression of the disease in a patient must determine the dimensions of the 
implants, these implants are customized to the patient and are “once-off” parts. 
Because of the customization of the implants and the nature of the life-threatening 
disease, there literally is no time for extensive trials. These implants therefore are 
not subject to regulation approval. This setup enables the manufacturer of these 
arthroplasties to respond to customer demands very quickly.  
 
Product improvement in orthopaedics in the future clearly must consider 
demographic developments in many countries. As their populations age, the number 
of (partial or total) hip and knee replacements is going to increase. An area which is 
going to attract considerable attention is the behaviour of such replacements when 
subjected to trauma (a person falling or being hit by a vehicle). The forces on 
orthopaedic implants in accidents are difficult to simulate in a dynamic situation, 
owing to lack of data about muscles, tendons, skeleton, and their interaction. The 
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behaviour of such bone / arthroplasty systems in cases where they are subjected to 
transient high strain-inducing loads is unknown and must be researched. 
 
 
Figure 6:  Orthopaedic Distal Radius Arthroplasty (Courtesy of ISIQU) 
 
3.  CONCLUSIONS 
 
The introduction of medical devices regulation in the South African medical devices 
market will lead to considerable market realignment and defragmentation. The 
opportunity is presented to focus on the purpose of a manufacturing company (to 
make the products that the customer wants). The need for a local certification 
authority was identified. It was concluded that the application of lean principles in 
the still-developing South African biomedical industry offers great advantages in 
allocating financial and personnel resources.  
 
It was further concluded that process improvements extend beyond technological 
improvements in a manufacturing environment. Seemingly unpredictable 
environments offer opportunities for standardization, leading to improved process 
efficiencies. 
 
Great opportunities and responsibilities rest with higher education institutions in the 
preparation of students (people), through appropriate curricula, to meet the 
demands of the biomedical industry. The tools available to achieve “zero defect”, 
interdisciplinary product development, should be part of the education of 
tomorrow’s engineers. 
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